A Stellar Launch For RSV Vaccine Arexvy Lifts GSK

 
• By Andrew McConaghie

GSK has enjoyed a better-than-expected launch for its RSV vaccine, but emphasized that it was still early days, and the firm is not altering its £3bn peak annual sales forecast for the product.

Walgreens Pharmacy
More than 90% of vaccinations have been administered through pharmacies, a trend believed to have favored GSK, and which it expects to continue.

More from Earnings

More from Business